On Thursday, in the course of current trade, Shares of Rite Aid Corporation (NYSE:RAD), dropped -1.90%, and is now trading at $7.76.
Today, Rite Aid declared sales results for April.
Monthly Sales
For the four weeks ended Apr. 25, 2015, same store sales raised 3.0 percent over the preceding-year period. April front-end same store sales, which were negatively influenced by 0.9 percent due to a shift in the timing of Easter, reduced 0.5 percent. Pharmacy same store sales, which comprised of an approximate 145 basis points negative impact from new generic introductions, raised 4.6 percent. Prescription count at comparable stores raised 1.8 percent over the preceding-year period.
Total drugstore sales for the four-week period raised 2.4 percent to $2.042 billion contrast to $1.995 billion for the same period last year. Prescription sales accounted for 68.9 percent of drugstore sales, and third party prescription sales represented 97.7 percent of pharmacy sales.
Year-to-Date
Same store sales for the 8-week period ended Apr. 25, 2015 raised 3.6 percent over the preceding-year period. Front-end same store sales raised 1.0 percent while pharmacy same store sales raised 4.9 percent. Prescription count at comparable stores raised 2.2 percent over the preceding-year period.
Total drugstore sales for the 8 weeks ended Apr. 25, 2015 raised 3.2 percent with sales of $4.068 billion contrast to $3.941 billion for the same period last year. Prescription sales represented 69.4 percent of total drugstore sales, and third party prescription sales represented 97.7 percent of pharmacy sales.
Rite Aid Corporation, through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other everyday and convenience products.
During an Afternoon trade, Shares of Time Warner Cable Inc. (NYSE:TWC), dipped -0.77%, and is now trading at $156.64.
Time Warner Cable, stated financial results for its first quarter ended March 31, 2015.
Financial Highlights
- First-quarter 2015 revenue grew 3.5% year over year with Business Services revenue up 16.9% and Residential Services revenue up 2.1%, the highest year-over-year organic growth in over 3 years.
- First-quarter Adjusted OIBDA was $2.0 billion – up 0.8% year over year. Operating Income of $1.1 billion reduced 0.7% year over year.
- Demonstrated disciplined administration of controllable costs; shared functions costs were flat year over year.
- Aggressive investments in technical operations and customer care, as well as higher programming costs and pension expense, moderated Adjusted OIBDA growth.
Revenue for the first quarter of 2015 raised 3.5% year over year as a result of revenue growth at the Business Services and Residential Services segments.
Operating Income for the first quarter of 2015 reduced 0.7% primarily due to higher depreciation expense, partially offset by lower merger-related and restructuring costs and higher Adjusted OIBDA. Merger-related and restructuring costs for the first quarter of 2015 comprised of $24 million of Comcast merger-related costs (comprising of employee retention costs of $14 million and advisory and legal fees of $10 million) and $2 million of restructuring costs primarily associated with employee terminations.
Time Warner Cable Inc., together with its auxiliaries, provides video, high-speed data, and voice services in the United States. It operates in three segments: Residential Services, Business Services, and Other Operations.
Shares of Celgene Corporation (NASDAQ:CELG), during its Thursday’s current trading session fell -3.92%, and is now trading at $108.82.
Celgene Corporation, stated net product sales of $2,055 million for the first quarter of 2015. Net product sales grew 20 percent from the same period in 2014 with operational growth of 22 percent. The negative net impact of currency on net product sales was 2 percent. First quarter total revenue raised 20 percent to $2,081 million contrast to $1,730 million in the first quarter of 2014. Adjusted net income for the first quarter of 2015 raised 26 percent to $891 million contrast to $705 million in the first quarter of 2014. For the same period, adjusted diluted earnings per share (EPS) raised 29 percent to $1.07 from $0.83, on a stock split-adjusted basis.
Based on U.S. GAAP (Generally Accepted Accounting Principles), Celgene stated first quarter of 2015 net income of $719 million or $0.86 per diluted share. For the first quarter of 2014, net income was $280 million or $0.33 per diluted share, on a stock split-adjusted basis.
In the first quarter of 2015, Celgene purchased about 9.5 million of its shares at a total cost of about $1,132 million. As of March 31, 2015, Celgene had $2,014 million remaining under its stock repurchase program.
Operating cash flow was $858 million in the first quarter of 2015. Celgene ended the quarter with $7,314 million in cash, cash equivalents and marketable securities.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
Finally, Teva Pharmaceutical Industries Limited (NYSE:TEVA), lost -2.27% Thursday.
Teva Pharmaceutical, stated results for the quarter ended March 31, 2015.
First Quarter 2015 Results
Revenues in the first quarter of 2015 amounted to $5.0 billion, in line with revenues in the first quarter of 2014. Not taking into account the impact of foreign exchange fluctuations and the divestment of the U.S. OTC plants, revenues grew 8%.
Exchange rate differences (net of profits from certain hedging transactions) between the first quarter of 2015 and the first quarter of 2014 reduced our revenues by $368 million and reduced our non-GAAP operating income by $42 million and our GAAP operating income by $23 million.
Non-GAAP gross profit was $3.1 billion in the first quarter of 2015, up 2% from the first quarter of 2014. Non-GAAP gross profit margin was 61.5% in the first quarter of 2015, contrast to 59.7% in the first quarter of 2014. GAAP gross profit was $2.8 billion in the first quarter of 2015, contrast to $2.7 billion in the first quarter of 2014. GAAP gross profit margin was 56.9% in the quarter, contrast to 53.9% in the first quarter of 2014.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
